3Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol, 2005, 6(6): 383-392. 被引量：1
4Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Aead Dermatol, 1999, 41(3 Pt 1): 401-407. 被引量：1
5Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy.J Am Acad Dermatol, 2005, 53(1 Suppl 1): S17-25. 被引量：1
6Charakida A, Dadzie O, Teixeira F, et al. Calcipotriol/beta- methasone dipropionate for the treatment of psoriasis.Expert Opin Pharmacother, 2006, 7(5): 597-606. 被引量：1
7Simonsen L, Hoy G, Didriksen E, et al. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Indust Pharm, 2004, 30( 10): 1095-1102. 被引量：1
8Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat, 2007, 18(6): 361-365. 被引量：1
9Vakirlis E, Kastanis A, loannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag, 2008, 4( 1 ): 141-148. 被引量：1
10Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol, 2006, 45(8 ): 970-975. 被引量：1
